446,964 Shares in Repligen Corporation $RGEN Bought by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC purchased a new position in Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 446,964 shares of the biotechnology company’s stock, valued at approximately $60,984,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. United Capital Financial Advisors LLC acquired a new position in shares of Repligen during the third quarter valued at about $368,387,000. Opti Capital Management LP acquired a new stake in shares of Repligen in the 4th quarter valued at about $2,399,209,000. Maverick Capital Ltd. acquired a new stake in shares of Repligen in the 1st quarter valued at about $178,946,000. Wasatch Advisors LP bought a new stake in Repligen in the 1st quarter valued at about $146,513,000. Finally, Price T Rowe Associates Inc. MD increased its position in Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after buying an additional 1,091,683 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Stock Performance

Shares of Repligen stock opened at $169.04 on Tuesday. The company has a market cap of $9.54 billion, a PE ratio of 231.56, a price-to-earnings-growth ratio of 3.04 and a beta of 1.03. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The business has a 50 day moving average price of $143.57 and a 200-day moving average price of $131.13. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on RGEN. Wolfe Research initiated coverage on Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective for the company. Zacks Research raised Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Evercore restated an “outperform” rating and set a $160.00 price target on shares of Repligen in a research note on Monday, July 6th. Finally, HSBC lowered their price objective on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $166.43.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.